نتایج جستجو برای: fabry disease

تعداد نتایج: 1493456  

2015
Yeo Jin Jeon Namhee Jung Joo-Won Park Hae-Young Park Sung-Chul Jung Jung Weon Lee

Fabry disease is a lysosomal storage disorder caused by deficiency of alpha-galactosidase A (α-gal A), which results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. Globotriaosylsphingosine (lyso-Gb3), a deacylated Gb3, is also increased in the plasma of patients with Fabry disease. Renal fibrosis is a key feature of advanced Fabry disease patients. Therefore, we e...

Journal: :Stroke 2002
David F Moore Gheona Altarescu Geoffrey S F Ling Neal Jeffries Karen P Frei Thais Weibel Gustavo Charria-Ortiz Raymond Ferri Andrew E Arai Roscoe O Brady Raphael Schiffmann

BACKGROUND AND PURPOSE Fabry disease is an X-linked inherited disorder resulting from a deficiency of alpha-galactosidase A. Cerebrovascular disease in Fabry disease includes small-vessel disease and larger-vessel ectasia in a predominantly posterior distribution. We assessed transcranial Doppler (TCD) blood flow velocities in naive and enzyme-treated Fabry patients. METHODS TCD was used to n...

Journal: :Stroke 2009
Katherine Sims Juan Politei Maryam Banikazemi Philip Lee

BACKGROUND AND PURPOSE Stroke is a common and serious clinical manifestation of Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A activity. This study was undertaken to better understand the natural history of cerebrovascular manifestations of Fabry disease. METHODS Data from 2446 patients in the Fabry Registry were analyzed to identify clinic...

2013
F Weidemann M Niemann S Störk F Breunig M Beer C Sommer S Herrmann G Ertl C Wanner

OBJECTIVE The long-term effects of enzyme-replacement therapy (ERT) in Fabry disease are unknown. Thus, the aim of this study was to determine whether ERT in patients with advanced Fabry disease affects progression towards 'hard' clinical end-points in comparison with the natural course of the disease. METHODS A total of 40 patients with genetically proven Fabry disease (mean age 40 ± 9 years...

2017
Sun Hee Heo Eungu Kang Yoon-Myung Kim Heounjeong Go Kyung Yong Kim Jae Yong Jung Minji Kang Gu-Hwan Kim Jae-Min Kim In-Hee Choi Jin-Ho Choi Sung-Chul Jung Robert J Desnick Han-Wook Yoo Beom Hee Lee

BACKGROUND Fabry disease is characterised by the progressive accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in vascular endothelial cells. Enzyme replacement therapy (ERT) clears this accumulation. We analysed plasma proteome profiles before and after ERT to characterise its molecular pathology. METHODS Two-dimensional electrophoresis and matrix-assisted laser deso...

Journal: :Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2014
Francisca Caetano Ana Botelho Paula Mota Joana Silva António Leitão Marques

Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by abnormalities of the GLA gene, which encodes the enzyme α-galactosidase A. A deficiency of this enzyme leads to the lysosomal accumulation of glycosphingolipids, which may cause left ventricular hypertrophy that is typically concentric and symmetric. We present the case of a 60-year-old woman with symptoms of dyspnea, at...

Journal: :AJNR. American journal of neuroradiology 2003
David F Moore Frank Ye Raphael Schiffmann John A Butman

BACKGROUND AND PURPOSE Fabry disease is a multisystem X-linked disorder characterized clinically by angiokeratoma, corneal and lenticular abnormalities, acroparesthesia, and renal and cardiac dysfunction and stroke. We sought to describe novel neuroimaging characteristics of Fabry disease. METHODS Neuroradiologic records of 104 hemizygous patients with Fabry disease evaluated between 1994 and...

2014
Takahiro Tsukimura Sachie Nakano Tadayasu Togawa Toshie Tanaka Seiji Saito Kazuki Ohno Futoshi Shibasaki Hitoshi Sakuraba

Fabry disease is an X-linked genetic disorder characterized by deficient activity of α-galactosidase A (GLA) and accumulation of glycolipids, and various GLA gene mutations lead to a wide range of clinical phenotypes from the classic form to the later-onset one. To investigate the biochemical heterogeneity and elucidate the basis of the disease using available clinical samples, we measured GLA ...

2016
Nora Seydelmann Dan Liu Johannes Krämer Christiane Drechsler Kai Hu Peter Nordbeck Andreas Schneider Stefan Störk Bart Bijnens Georg Ertl Christoph Wanner Frank Weidemann

BACKGROUND High-sensitivity troponin (hs-TNT), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs-TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow-up study to assess longitudinal hs-TNT changes relative to fibrosis and cardiomyopathy progression. METHODS ...

2010
Jeong-Yup Kim Young-Youl Hyun Ji-Eun Lee Hye-Ran Yoon Gu-Hwan Kim Han-Wook Yoo Seong-Tae Cho No-Won Chun Byoung-Chunn Jeoung Hwa-Jung Kim Keong-Wook Kim Seong-Nam Kim Yung-A Kim Hyun-Ah Lee Jong-Young Lee Yung-Chun Lee Hun-Kwan Lim Keong-Sik Oh Seong-Hwan Son Beong-Hee Yu Kyeong-So Wee Eun-Jong Lee Young-Ki Lee Jung-Woo Noh Seung-Jung Kim Kyu-Bok Choi Suk-Hee Yu Heui-Jung Pyo Young-Joo Kwon

BACKGROUND/AIMS Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. METHODS A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were m...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید